The p53 tumor suppressor network in cancer and the therapeutic modulation of cell death

被引:54
作者
Chari, Nikhil S. [1 ]
Pinaire, Nicole L. [1 ]
Thorpe, Lynnelle [1 ]
Medeiros, L. Jeffrey [1 ]
Routbort, Mark J. [1 ]
McDonnell, Timothy J. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
关键词
Apoptosis; p53; Therapy; Cancer; MicroRNA; Tumor suppressors; SMALL-MOLECULE INHIBITORS; MDM2 GENE AMPLIFICATION; DOWN-REGULATION; BCL-2; FAMILY; DNA-DAMAGE; STEM-CELLS; TRANSCRIPTIONAL ACTIVATION; P53-DEPENDENT APOPTOSIS; T-ANTIGEN; EXPRESSION;
D O I
10.1007/s10495-009-0327-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The molecular subversion of cell death is acknowledged as a principal contributor to the development and progression of cancer. The p53 tumor suppressor protein is among the most commonly altered proteins in human cancer. The p53 protein mediates critical functions within cells including the response to genotoxic stress, differentiation, senescence, and cell death. Loss of p53 function can result in enhanced rates of cell proliferation, resistance to cell death stimuli, genomic instability, and metastasis. The community of cancer scientists is now in possession of a vast repository of information regarding the frequency, specific mechanisms, and clinical context of cell death deregulation in cancer. This information has enabled the design of therapeutic agents to target proteins, including p53. The feasibility and impact of targeting cell death signaling proteins has been established in preclinical models of human cancer. The appropriate application of these targeted agents is now being established in clinical trials.
引用
收藏
页码:336 / 347
页数:12
相关论文
共 174 条
[1]   Prospective identification of tumorigenic breast cancer cells [J].
Al-Hajj, M ;
Wicha, MS ;
Benito-Hernandez, A ;
Morrison, SJ ;
Clarke, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988
[2]   ES cells do not activate p53-dependent stress responses and undergo p53-independent apoptosis in response to DNA damage [J].
Aladjem, MI ;
Spike, BT ;
Rodewald, LW ;
Hope, TJ ;
Klemm, M ;
Jaenisch, R ;
Wahl, GM .
CURRENT BIOLOGY, 1998, 8 (03) :145-155
[3]   Gli and hedgehog in cancer:: Tumours, embryos and stem cells [J].
Altaba, AR ;
Sánchez, P ;
Dahmane, N .
NATURE REVIEWS CANCER, 2002, 2 (05) :361-372
[4]   Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains [J].
Ang, Hwee Ching ;
Joerger, Andreas C. ;
Mayer, Sebastian ;
Fersht, Alan R. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (31) :21934-21941
[5]   A chromatin-associated and transcriptionally inactive p53-Mdm2 complex occurs in mdm2 SNP309 homozygous cells [J].
Arva, NC ;
Gopen, TR ;
Talbott, KE ;
Campbell, LE ;
Chicas, A ;
White, DE ;
Bond, GL ;
Levine, AJ ;
Bargonetti, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (29) :26776-26787
[6]   CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS [J].
BAKER, SJ ;
FEARON, ER ;
NIGRO, JM ;
HAMILTON, SR ;
PREISINGER, AC ;
JESSUP, JM ;
VANTUINEN, P ;
LEDBETTER, DH ;
BARKER, DF ;
NAKAMURA, Y ;
WHITE, R ;
VOGELSTEIN, B .
SCIENCE, 1989, 244 (4901) :217-221
[7]   MDM2 EXPRESSION IS INDUCED BY WILD TYPE-P53 ACTIVITY [J].
BARAK, Y ;
JUVEN, T ;
HAFFNER, R ;
OREN, M .
EMBO JOURNAL, 1993, 12 (02) :461-468
[8]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[9]   Tissue repair and stem cell renewal in carcinogenesis [J].
Beachy, PA ;
Karhadkar, SS ;
Berman, DM .
NATURE, 2004, 432 (7015) :324-331
[10]   P53 and the pathogenesis of skin cancer [J].
Benjamin, Cara L. ;
Ananthaswamy, Honnavara N. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2007, 224 (03) :241-248